These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 11861387

  • 21. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
    Modesitt SC, Parsons SJ.
    Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
    [Abstract] [Full Text] [Related]

  • 22. [Effects of PI3K/Akt/NF-κB signal pathway on FSH facilitation on cell proliferation and invasion by human epithelial ovarian cancer].
    Xu CL, Lu XL, Yan XN, Wang HL, Chen SQ.
    Zhonghua Fu Chan Ke Za Zhi; 2012 Feb; 47(2):134-8. PubMed ID: 22455747
    [Abstract] [Full Text] [Related]

  • 23. Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo.
    Denlinger CE, Rundall BK, Jones DR.
    J Thorac Cardiovasc Surg; 2005 Nov; 130(5):1422-9. PubMed ID: 16256798
    [Abstract] [Full Text] [Related]

  • 24. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.
    Zhou C, Qiu L, Sun Y, Healey S, Wanebo H, Kouttab N, Di W, Yan B, Wan Y.
    Int J Oncol; 2006 Jul; 29(1):269-78. PubMed ID: 16773209
    [Abstract] [Full Text] [Related]

  • 25. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft.
    Chen P, Wen X, Wang B, Hou D, Zou H, Yuan Q, Yang H, Xie J, Huang H.
    Ann Hematol; 2018 May; 97(5):865-875. PubMed ID: 29450644
    [Abstract] [Full Text] [Related]

  • 26. Combinatorial therapy with adenoviral-mediated PTEN and a PI3K inhibitor suppresses malignant glioma cell growth in vitro and in vivo by regulating the PI3K/AKT signaling pathway.
    Nan Y, Guo L, Song Y, Wang L, Yu K, Huang Q, Zhong Y.
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1477-1487. PubMed ID: 28401302
    [Abstract] [Full Text] [Related]

  • 27. Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo.
    Liu Y, Cui B, Qiao Y, Zhang Y, Tian Y, Jiang J, Ma D, Kong B.
    Int J Gynecol Cancer; 2011 Jan; 21(1):100-5. PubMed ID: 21330835
    [Abstract] [Full Text] [Related]

  • 28. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
    Yu C, Rahmani M, Dai Y, Conrad D, Krystal G, Dent P, Grant S.
    Cancer Res; 2003 Apr 15; 63(8):1822-33. PubMed ID: 12702569
    [Abstract] [Full Text] [Related]

  • 29. Phosphatidylinositol 3-kinase inhibition by LY294002 radiosensitizes human cervical cancer cell lines.
    Lee CM, Fuhrman CB, Planelles V, Peltier MR, Gaffney DK, Soisson AP, Dodson MK, Tolley HD, Green CL, Zempolich KA.
    Clin Cancer Res; 2006 Jan 01; 12(1):250-6. PubMed ID: 16397049
    [Abstract] [Full Text] [Related]

  • 30. Synergism of PI3K/Akt inhibition and Fas activation on colon cancer cell death.
    Zhu L, Derijard B, Chakrabandhu K, Wang BS, Chen HZ, Hueber AO.
    Cancer Lett; 2014 Nov 28; 354(2):355-64. PubMed ID: 25199763
    [Abstract] [Full Text] [Related]

  • 31. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ, Heo JH, Park JY, Jeong JY, Cho HJ, Park KS, Kim SH, Moon YW, Kim JS, An HJ.
    Gynecol Oncol; 2019 Apr 28; 153(1):135-148. PubMed ID: 30686552
    [Abstract] [Full Text] [Related]

  • 32. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K, Eder IE, Putz T, Ramoner R, Culig Z, Ueberall F, Bartsch G, Klocker H.
    Prostate; 2004 Feb 15; 58(3):259-68. PubMed ID: 14743465
    [Abstract] [Full Text] [Related]

  • 33. Dual blockade of phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer.
    Xu R, Nakano K, Iwasaki H, Kumagai M, Wakabayashi R, Yamasaki A, Suzuki H, Mibu R, Onishi H, Katano M.
    Cancer Lett; 2011 Jul 28; 306(2):151-60. PubMed ID: 21429662
    [Abstract] [Full Text] [Related]

  • 34. The phosphatidylinositol 3-kinase/AKT signal transduction pathway plays a critical role in the expression of p21WAF1/CIP1/SDI1 induced by cisplatin and paclitaxel.
    Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, Testa JR.
    Cancer Res; 2000 Oct 01; 60(19):5390-4. PubMed ID: 11034077
    [Abstract] [Full Text] [Related]

  • 35. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells.
    Lane D, Robert V, Grondin R, Rancourt C, Piché A.
    Int J Cancer; 2007 Sep 15; 121(6):1227-37. PubMed ID: 17534891
    [Abstract] [Full Text] [Related]

  • 36. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
    Furuya F, Lu C, Willingham MC, Cheng SY.
    Carcinogenesis; 2007 Dec 15; 28(12):2451-8. PubMed ID: 17660507
    [Abstract] [Full Text] [Related]

  • 37. Effect of PI3K/Akt pathway inhibition-mediated G1 arrest on chemosensitization in ovarian cancer cells.
    Fekete M, Santiskulvong C, Eng C, Dorigo O.
    Anticancer Res; 2012 Feb 15; 32(2):445-52. PubMed ID: 22287731
    [Abstract] [Full Text] [Related]

  • 38. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer.
    Cooper AL, Greenberg VL, Lancaster PS, van Nagell JR, Zimmer SG, Modesitt SC.
    Gynecol Oncol; 2007 Mar 15; 104(3):596-601. PubMed ID: 17049973
    [Abstract] [Full Text] [Related]

  • 39. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with paclitaxel.
    Tedjarati S, Baker CH, Apte S, Huang S, Wolf JK, Killion JJ, Fidler IJ.
    Clin Cancer Res; 2002 Jul 15; 8(7):2413-22. PubMed ID: 12114447
    [Abstract] [Full Text] [Related]

  • 40. The synergistic killing of AML cells co-cultured with HS-5 bone marrow stromal cells by As2O3 and the PI3K/Akt signaling pathway inhibitor LY294002.
    Chen P, Wu J, Yuan Q, Jiang X, Huang H.
    Pharmazie; 2015 May 15; 70(5):322-7. PubMed ID: 26062301
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.